General Information of This Target
Target ID
PATR0YTGZR
Target Name
Nicotinamide phosphoribosyltransferase (NAMPT)
Gene Name
NAMPT
Gene ID
10135
Synonym
PBEF, PBEF1; Pre-B-cell colony-enhancing factor 1; Visfatin
Sequence
MNPAAEAEFNILLATDSYKVTHYKQYPPNTSKVYSYFECREKKTENSKLRKVKYEETVFY
GLQYILNKYLKGKVVTKEKIQEAKDVYKEHFQDDVFNEKGWNYILEKYDGHLPIEIKAVP
EGFVIPRGNVLFTVENTDPECYWLTNWIETILVQSWYPITVATNSREQKKILAKYLLETS
GNLDGLEYKLHDFGYRGVSSQETAGIGASAHLVNFKGTDTVAGLALIKKYYGTKDPVPGY
SVPAAEHSTITAWGKDHEKDAFEHIVTQFSSVPVSVVSDSYDIYNACEKIWGEDLRHLIV
SRSTQAPLIIRPDSGNPLDTVLKVLEILGKKFPVTENSKGYKLLPPYLRVIQGDGVDINT
LQEIVEGMKQKMWSIENIAFGSGGGLLQKLTRDLLNCSFKCSYVVTNGLGINVFKDPVAD
PNKRSKKGRLSLHRTPAGNFVTLEEGKGDLEEYGQDLLHTVFKNGKVTKSYSFDEIRKNA
QLNIELEAAHH

    Click to Show/Hide
Family
the NAPRTase family
Function
Catalyzes the condensation of nicotinamide with 5- phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. It is the rate limiting component in the mammalian NAD biosynthesis pathway. The secreted form behaves both as a cytokine with immunomodulating properties and an adipokine with anti-diabetic properties, it has no enzymatic activity, partly because of lack of activation by ATP, which has a low level in extracellular space and plasma. Plays a role in the modulation of circadian clock function. NAMPT-dependent oscillatory production of NAD regulates oscillation of clock target gene expression by releasing the core clock component: CLOCK-BMAL1 heterodimer from NAD-dependent SIRT1- mediated suppression.

    Click to Show/Hide
Uniprot Entry
NAMPT_HUMAN
HGNC ID
HGNC:30092
KEGG ID
hsa:10135
Full List of The ADC Related to This Target
Investigative
Click To Hide/Show 18 ADC Related to This Stage
ADC Info ADC Name Antibody Antigen Payload Linker Ref
HER2-EC4 DAR7.8
Anti-human HER2 mAb
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NAMPT inhibitor 5
Open-chain glycine maleimide
[1]
B7H3-EC3 DAR4.1
Anti-human CD276 mAb
CD276 antigen (CD276)
NAMPT inhibitor 4
Mc-Val-Ala
[1]
B7H3-EC3 DAR7.8
Anti-human CD276 mAb
CD276 antigen (CD276)
NAMPT inhibitor 4
Mc-Val-Ala
[1]
C4.4A-EC4
Anti-human LYPD3 mAb
Ly6/PLAUR domain-containing protein 3 (LYPD3)
NAMPT inhibitor 5
Open-chain glycine maleimide
[1]
HER2-EC5
Anti-human HER2 mAb
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NAMPT inhibitor 6
Open-chain glycine maleimide-PEG
[1]
HER2-EC4 DAR2.7
Anti-human HER2 mAb
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NAMPT inhibitor 5
Open-chain glycine maleimide
[1]
HER2-EC3
Anti-human HER2 mAb
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NAMPT inhibitor 4
Mc-Val-Ala
[1]
HER2-EC1
Anti-human HER2 mAb
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
NAMPT inhibitor 4
Maleimido-caproyl
[1]
C4.4A-EC5
Anti-human LYPD3 mAb
Ly6/PLAUR domain-containing protein 3 (LYPD3)
NAMPT inhibitor 6
Open-chain glycine maleimide-PEG
[2]
C4.4A-EC3
Anti-human CD276 mAb
Ly6/PLAUR domain-containing protein 3 (LYPD3)
NAMPT inhibitor 4
Mc-Val-Ala
[1]
C4.4A-EC2
Anti-human LYPD3 mAb
Ly6/PLAUR domain-containing protein 3 (LYPD3)
NAMPT inhibitor 6
Maleimido-caproyl
[1]
C4.4A-EC1
Anti-human LYPD3 mAb
Ly6/PLAUR domain-containing protein 3 (LYPD3)
NAMPT inhibitor 4
Maleimido-caproyl
[1]
B7H3-EC5
Anti-human CD276 mAb
CD276 antigen (CD276)
NAMPT inhibitor 6
Open-chain glycine maleimide-PEG
[1]
B7H3-EC4
Anti-human CD276 mAb
CD276 antigen (CD276)
NAMPT inhibitor 5
Open-chain glycine maleimide
[1]
B7H3-EC2
Anti-human CD276 mAb
CD276 antigen (CD276)
NAMPT inhibitor 6
Maleimido-caproyl
[1]
B7H3-EC1
Anti-human CD276 mAb
CD276 antigen (CD276)
NAMPT inhibitor 4
Maleimido-caproyl
[1]
CD206-NAMPT inhibitor-based antibody drug conjugate
Undisclosed
Macrophage mannose receptor 1 (MRC1)
NAMPT toxophore
Undisclosed
[3]
Alpha-human dectin-1-pam3 conjugate
Undisclosed
C-type lectin domain family 7 member A (CLEC7A)
NAMPT toxophore
Undisclosed
[4]
References
Ref 1 A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer Therapy. Bioconjug Chem. 2022 Jun 15;33(6):1210-1221.
Ref 2 Taxol(r) structure-activity-relationships - synthesis and biological evaluation of taxol analogs modified at c-7. Bioorg Med Chem Lett. 1994;4(18):2223-2228.
Ref 3 Effective depletion of M2 macrophages by CD206-NAMPT-ADCs. Cancer Res (2020) 80 (16_Supplement): 677.
Ref 4 Introduction to basic information on ADC drug alpha-human Dectin-1-Pam3 conjugate(Dynavax Technologies).